It has been shown that GSK-3β positively regulates NF-κB–mediated survival of cancer cells and that the inhibition of GSK-3β decreases cancer cell survival via suppression of NF-κB–mediated Bcl-2 and XIAP expression in leukemia7, pancreatic8, and renal cancer cells10. This evidence concerns the gene NFKB1 and renal carcinoma.